vitamin-b-12 and Hearing-Loss--Sensorineural

To assess the efficacy of the combination of hyperbaric oxygen (HBO) and pharmacological treatment in patients with idiopathic sudden sensorineural hearing loss (ISSNHL) and define patients amenable for HBO therapy.. Prospective, randomized, trial involving 136 cases with unilateral ISSNHL that were randomly divided into 2 groups: the pharmacological treatment (P) group and HBO + pharmacological treatment (HBO+P) group, which received additional HBO for 14 days besides the pharmacological treatments. Pure tone audiometry gain larger than 15 dBHL was defined as success, and the success rate of each group was calculated.. The overall success rate of the HBO+P group and the P group is 60.6% (40/66) and 42.9% (30/70), respectively (p < 0.05). Furthermore, patients with mild-moderate baseline hearing loss, aged ≤50 years, receiving treatment in ≤14 days, or without accompanied dizziness/vertigo in the HBO+P group had higher success rate than the P group (p < 0.05).. HBO combined with pharmacological treatments leads to better hearing recovery than pharmacological treatments alone.

Topics: Adult; Aged; Audiometry, Pure-Tone; Combined Modality Therapy; Drugs, Chinese Herbal; Evoked Potentials, Auditory, Brain Stem; Female; Flunarizine; Glucocorticoids; Hearing Loss, Sensorineural; Hearing Loss, Sudden; Humans; Hyperbaric Oxygenation; Male; Middle Aged; Nerve Growth Factor; Prednisone; Prospective Studies; Thiamine; Treatment Outcome; Vasodilator Agents; Vitamin A; Vitamin B 12; Vitamin E; Vitamins; Young Adult

Vascular disease and its risk factors have been associated with the age-related hearing loss. We examined the association of elevated plasma homocysteine and its determinants with hearing levels. Pure-tone air conduction thresholds in 728 individuals with sensorineural hearing loss were not associated with homocysteine, erythrocyte folate and Vitamin B6. Low concentrations of serum folate and Vitamin B12 were associated with better hearing. When folate status was below the median, 5,10-methylenetetrahydrofolate reductase (MTHFR) 677TT homozygotes had similar hearing levels to subjects with a C allele. However, when folate status was above the median, MTHFR 677TT homozygotes had on an average 5 dB (p = 0.037) and 2.6 dB (p = 0.021) lower PTA-high and PTA-low hearing thresholds, respectively, than the subjects with a 677C allele. The relationship between serum folate and hearing thresholds appeared to be dependent on MTHFR 677 genotype (CC, r = 0.13, p = 0.034; TT, r = -0.10, p = 0.291). This supports the hypothesis that a greater one-carbon moiety commitment to de novo synthesis of nucleotides and an increase in formyl-folate derivatives relative to methyl-folate derivatives is protective for hearing.

Topics: 5,10-Methylenetetrahydrofolate Reductase (FADH2); Aged; Auditory Threshold; Female; Folic Acid; Genetic Predisposition to Disease; Hearing Loss, Sensorineural; Homocysteine; Humans; Incidence; Male; Middle Aged; Mutation; Netherlands; Polymorphism, Genetic; Risk Assessment; Risk Factors; Severity of Illness Index; Vitamin B 12

Topics: Adult; Anus, Imperforate; Ectodermal Dysplasia; Growth Disorders; Hearing Loss, Sensorineural; Humans; Hypothyroidism; Intellectual Disability; Male; Nose; Pancreatic Diseases; Pancytopenia; Vitamin B 12; Vitamin B 12 Deficiency; Young Adult

Relapsing polychondritis is a rare disease of unknown etiology causing systematic inflammation of the whole cartilaginous tissues. We report a patient with relapsing polychondritis preceded by inner ear involvement. A 68-year-old female visited our hospital for a chief complaint of sudden bilateral hearing loss. On pure-tone audiometry, sensorineural hearing loss, 47dB on the right and 51dB on the left, was observed. Later, bilateral auricular chondritis and uveitis developed. On biopsy of the auricular cartilage, perichondritis was observed. The patient was diagnosed with relapsing polychondritis in the early stage, 2 weeks after the onset. Oral predonine administration was initiated, and the auricular inflammation was improved within 10 days. The hearing loss disorder was gradually improved. The steroid dose was reduced, and no decrease in hearing has been observed so far.

Topics: Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents; Audiometry, Pure-Tone; Biopsy; Ear, Inner; Female; Hearing Loss, Sensorineural; Humans; Polychondritis, Relapsing; Prednisolone; Severity of Illness Index; Uveitis; Vitamin B 12

Topics: Child; Child, Preschool; Female; Hearing Loss, Sensorineural; Humans; Mumps; Thiamine; Vasodilator Agents; Vitamin B 12